Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Santen Anticipates Continued Growth in Sales of Ikervis in Europe; 30% Overseas Sales Ratio an “Achievable Target”
May 17, 2016
- As Tagrisso Launch Nears, AZ Pushes Stringent Prerequisites for Facilities, Doctors to Ensure Safety
May 17, 2016
- Towa to Mull Over Distribution Dealing with Wholesalers
May 17, 2016
- Eisai Aims for 10% Rise in Japan Pharma Sales with Patented Products: CEO
May 16, 2016
- Eisai Posts Higher Profits despite Sales Dip, Global Brands Expand
May 16, 2016
- Kyorin Enthusiastic about Overcoming “Kipres Cliff,” Aiming for Over 50% Share with AG, 4 New Product Launches
May 16, 2016
- Ono to Erect New Opdivo Plant, Operational Launch Eyed for 2020
May 13, 2016
- US Merck Links Up with Univ. of Tokyo on Drug Discovery
May 13, 2016
- Takeda Taps Ex-Kraft Foods CFO Kehoe as New CFO
May 13, 2016
- Daiichi Sankyo CEO Sees High Odds of Success for AML Drug Quizartinib
May 13, 2016
- Daiichi Sankyo Sees 7.3% Sales Rise, but Girding for FY2016 Dip on Olmesartan Cliff
May 13, 2016
- Kissei Ditches Constipation Drug KWA-0711, Turns to Other Products for GI Entry
May 13, 2016
- Nichi-Iko to Develop 3 Biosimilars for Global Market, Aims to Enter as Global Top-10 Generic Maker within 3 Years
May 13, 2016
- Santen’s FY2015 Profits Zoom on Sale of RA Business
May 13, 2016
- Astellas Unveils List of Approval Hopefuls in FY2016
May 12, 2016
- Astellas Looking at Japan Filing of Romosozumab by March 2017
May 12, 2016
- Under New Name, Ocata Positioned as R&D Hub for Regenerative Medicine, Ophthalmology: Astellas
May 12, 2016
- Sumitomo Dainippon’s Sales Cross 400 Billion Yen as Latuda Becomes Blockbuster in N. America
May 12, 2016
- Shionogi Scores Record Operating Profit as Royalties Spike
May 12, 2016
- Mitsubishi Tanabe’s Sales Rise on Royalty, Upfront Revenues
May 12, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…